A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers

2024-512510-17-00 Protocol HP7040-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 5 Aug 2024 · End 25 Feb 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol HP7040-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 112
Countries 1
Sites 1

Treatment of pain

Key facts

Sponsor
Gruenenthal GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]
Trial duration
5 Aug 2024 → 25 Feb 2026
Decision date (initial)
2024-07-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512510-17-00
WHO UTN
U1111-1307-3561

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Treatment of pain

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Gruenenthal GmbH

Sponsor organisation
Gruenenthal GmbH
Address
Zieglerstrasse 6
City
Aachen
Postcode
52078
Country
Germany

Scientific contact point

Organisation
Gruenenthal GmbH
Contact name
Grünenthal Trial Information Desk

Public contact point

Organisation
Gruenenthal GmbH
Contact name
Grünenthal Trial Information Desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 112 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
CRS Clinical Research Services Management GmbH
Clinical Unit, Grenadierstrasse 1, Neckarstadt, Mannheim

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-08-05 2026-02-25 2024-08-05 2026-01-26

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-30 Germany Acceptable
2024-07-09
2024-07-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-09-27 Germany Acceptable
2024-07-09
2024-09-27
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-05-21 Germany Acceptable
2024-07-09
2025-05-21
4 SUBSTANTIAL MODIFICATION SM-1 2025-08-27 Germany Acceptable
2025-10-20
2025-10-20